R-Loops and Their Key Role in Cancer Research
R-loops are being investigated as potential therapeutic targets for cancer. Find out what they are, how they form, how their formation is controlled by our cells, and, above all, their potential as therapeutic targets.
Say Hello to Your Littlest Friends — the Microbiota
How well do you understand your microbiota? Dr. Allyson Byrd of Genentech, the fourth guest on Brilliant Science, is a bioinformatician focusing on parsing all the data our microbiomes have to offer. Read about the value of analyzing microbiota and how Dr. Byrd hopes to leverage the results.
Finding New Horizons — What Possibilities Exist with Single-Cell Analysis?
Single-cell techniques offer exciting, new ways to understand personalized medicine and research. Developing these techniques at Bio-Rad is Dr. Kelly Kaihara, the third guest on Brilliant Science. Read about what makes single-cell analysis different and Kaihara’s perspective on its potential moving forward.
The Benefits of Flow Cytometry in Immuno-Oncology Research
Immuno-oncology, or cancer immunotherapy, research focuses heavily on the various types of cells and their behavior in cancer, so the use of flow cytometry to interrogate these cells is a no brainer. See how flow cytometry fits in this growing field of research and how it can help identify new targets and improve drug design to generate more effective and safer cancer therapeutics.
Phagocytosis and Phasing Out Disease
Our immune systems could soon hold the key to rewriting disease and disorder treatments. Studying the inner workings of the immune system’s primary weapon, the macrophage, with the help of CRISPR is Dr. Adam Hoppe at SDSU. Read more about his exciting work and what he hopes to accomplish next.
The Potential for CRISPR Gene Editing in HIV
The advent of CRISPR as a gene editing tool appears to have revolutionized drug discovery and development in a very short time. CRISPR-Cas9 technology is also being utilized to target HIV, to mutate or cut out the provirus. Read about what’s new in potential treatments for HIV and the challenges facing the industry.
NYU Prof Harnesses CRISPR to End Muscular Dystrophy
On the scientific horizon are possibilities of curing genetic disorders and altering disease management — all because of CRISPR. Investigating exciting approaches to reversing the effects of muscular dystrophy with the help of CRISPR is Dr. Chengzu Long at NYU. Read more about his life, his work, and where he sees CRISPR going next.
The Ups and Downs of Biosimilar Development
In this podcast, biosimilar key opinion leader Dr. Paul Rhyne provides an overview of the current state of biosimilars and their global impact. Leveraging his 20+ years of experience in developing biologics, he discusses how cost and patient access play a big role in this new field of research.
Biosimilars: Providing More Treatment Options
It is hoped that the development of biosimilars will lead to more accessible and cost-effective treatment options. Here we explore the current opportunities for biosimilars in rheumatoid arthritis and discuss the opportunities and concerns tied to their use.
What’s New in U.S. Biosimilar-Land?
Biosimilars are gaining in popularity and estimates predict that the U.S. could save between $40–250 billion in healthcare costs over the next decade by switching from biologics to biosimilars. See how biosimilars have gained in popularity recently, the challenges the U.S. faces in developing them, and what the future holds.